Damora Therapeutics, Inc. Ordinary Shares (DMRA) is a publicly traded the market company. As of November 2, 2026, DMRA trades at $21.50 with a market cap of $1.33B and a P/E ratio of 2.74. DMRA moved +0.05% today. Year to date, DMRA is +0.00%; over the trailing twelve months it is flat. Its 52-week range spans $16.50 to $34.89. Analyst consensus is strong buy with an average price target of $46.67. Rallies surfaces DMRA's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies tracks politician and congressional stock disclosures for DMRA, including purchases, sales, transaction dates, owners, and reported trade amounts when available.
| Metric | Value |
|---|---|
| Price | $21.50 |
| Market Cap | $1.33B |
| P/E Ratio | 2.74 |
| EPS | $7.49 |
| Dividend Yield | 0.00% |
| 52-Week High | $34.89 |
| 52-Week Low | $16.50 |
| Volume | 402 |
| Avg Volume | 0 |
| Revenue (TTM) | $8.17M |
| Net Income | $-262.82M |
| Gross Margin | 0.00% |
7 analysts cover DMRA: 0 strong buy, 7 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $46.67.